Antimalarial drug touted by President Trump is linked to increased risk of death in coronavirus patients, study says

By Steve Mogbo   1 week ago   106
Health - Top Stories

A study of 96,000 hospitalized coronavirus patients on six continents found that those who received an antimalarial drug promoted by President Trump as a “game changer” in the fight against the virus had a significantly higher risk of death compared with those who did not. 

 

People treated with hydroxychloroquine, or the closely related drug chloroquine, were also more likely to develop a type of irregular heart rhythm, or arrhythmia, that can lead to sudden cardiac death, it concluded. 

The study, published Friday in the medical journal the Lancet, is the largest analysis to date of the risks and benefits of treating covid-19 patients with antimalarial drugs.

It is based on a retrospective analysis of medical records, not a controlled study in which patients are divided randomly into treatment groups — a method considered the gold standard of medicine. But the sheer size of the study was convincing to some scientists.

“It’s one thing not to have benefit, but this shows distinct harm,” said Eric Topol, a cardiologist and director of the Scripps Research Translational Institute. “If there was ever hope for this drug, this is the death of it.” 

David Maron, director of preventive cardiology at the Stanford University School of Medicine, said that “these findings provide absolutely no reason for optimism that these drugs might be useful in the prevention or treatment of covid-19.”

Past studies also found scant or no evidence of hydroxychloroquine’s benefit in treating sick patients, while reports mounted of dangerous heart problems associated with its use. As a result, the Food and Drug Administration last month warned against the use of the drug outside hospital settings or clinical trials. 

The new analysis — by Mandeep Mehra, a Harvard Medical School professor and physician at Brigham and Women’s Hospital, and colleagues at other institutions — included patients with a positive laboratory test for covid-19 who were hospitalized between Dec. 20, 2019, and April 14, 2020, at 671 medical centers worldwide. The mean age was 54 years, and 53 percent were men. Those who were on mechanical ventilators or who received remdesivir, an antiviral drug made by Gilead Sciences that has shown promise in decreasing recovery times, were excluded. 

Mehra said in an interview that the widespread use of antimalarials for covid-19 patients was based on the idea of “a desperate disease demands desperate measures," but that we have learned a hard lesson from the experience about the importance of first doing no harm.

In retrospect, Mehra said, using the drugs without systematic testing was “unwise.”

“I wish we had had this information at the outset,” he said, “as there has potentially been harm to patients.”

Nearly 15,000 of the 96,000 patients in the analysis were treated with hydroxychloroquine or chloroquine alone or in combination with a type of antibiotics known as a macrolide, such as azithromycin or clarithromycin, within 48 hours of their diagnosis.

The difference between patients who received the antimalarials and those who did not was striking.

For those given hydroxychloroquine, there was a 34 percent increase in risk of mortality and a 137 percent increased risk of a serious heart arrhythmias. For those receiving hydroxychloroquine and an antibiotic — the cocktail endorsed by Trump — there was a 45 percent increased risk of death and a 411 percent increased risk of serious heart arrhythmias.

Those given chloroquine had a 37 percent increased risk of death and a 256 percent increased risk of serious heart arrhythmias. For those taking chloroquine and an antibiotic, there was a 37 percent increased risk of death and a 301 percent increased risk of serious heart arrhythmias. 

Cardiologist Steven Nissen of the Cleveland Clinic said the new data, combined with data from smaller previous studies, suggests that the drug “is maybe harmful and that no one should be taking it outside of a clinical trial.” 

Jesse Goodman, a former FDA chief scientist who is now a Georgetown University professor, called the report “very concerning.” He noted, however, that it is an observational study, rather than a randomized controlled trial, so it shows correlation  between the drugs and certain outcomes, rather than a clear cause and effect.

[NewsNaira]



Share this article!



Login to comment and earn


Chibundu
1 week ago

Wow I love that


(Quote) (Likes)

May God guide us from this calamity


(Quote) (Likes)

Ffkobvwdgopnvdfjnvv


(Quote) (Likes)

Then do something about it


(Quote) (Likes)
Is donald a medical practioner?
(Quote) (Likes)
Junior
1 week ago

Thanks for the information 


(Quote) (Likes)
Chibundu
1 week ago

Trump is really trying 


(Quote) (Likes)

I know it will 


(Quote) (Likes)
Numa Ikwesiri
1 week ago

is Donald Trump a medical doctor?


(Quote) (Likes)

Hxgg No me a lot and you want 


(Quote) (Likes)

Lord we need ur Guidence


(Quote) (Likes)
Edward Nnamdi
1 week ago

Hmmm!! OK oo


(Quote) (Likes)
Israelp
1 week ago

Issalright lemme sleep


(Quote) (Likes)
Usoro Inemesit
1 week ago

Okay na let's see


(Quote) (Likes)

Nawaoooo.. This is serious. God save us


(Quote) (Likes)
Hussaina Adamu
1 week ago

That is what they want ooo


(Quote) (Likes)

We need corona drugs 


(Quote) (Likes)
Linus Utsalo
1 week ago

Wow I love that too


(Quote) (Likes)
Apakhi Elijah
1 week ago

How will it be so.. 


(Quote) (Likes)
Kings O Kings
1 week ago

I know they will kick against hi


(Quote) (Likes)


What is News₦aira Income Program(News₦IP)

  • News₦aira Income Program (News₦IP) is a system aimed at raising revenue for registered users that browse the NewsNaira Website. An online program driven by a goal of solving the financial problems among the youths, students, middle class and whoever wishes to take advantage of earning opportunity and making money online legitimately in Nigeria as it creates the channel for participants to earn residual income on weekly basis.
more

How News₦IP Works

  • News₦aira has 2 means of generating income for our members.
    News₦AP: NewsNaira Affiliate Program - With News₦AP, participants earns ₦1,000 whenever they refer anyone to join NewsNaira Income Program. There is no limit to how many people you can refer.

    News₦ARS: NewsNaira Ad Revenue Sharing - With News₦ARS, participants earns residual income bonus by reading news, commentting on articles, publishing forum posts, daily login to their NewsNaira account, and even sharing assigned sponsored post on social media.

    We share our ads revenue with you weekly when you make NewsNaira community your news and information household.
more